Remiges Ventures

Remiges Ventures is a cross-border venture capital firm primarily focused on the life sciences sector, with a particular emphasis on drug discovery and development. The firm actively engages in company creation, leveraging intellectual properties from Japanese academia to establish innovative ventures. Beyond incubation, Remiges Ventures also takes lead positions in syndicating Series A and later-stage investment rounds globally, supporting the growth of therapeutic companies. They manage RDiscovery, an incubator dedicated to nurturing early-stage drug discovery seeds and advancing them towards more mature development stages.

The firm was founded in 2014 by Taro Inaba, who brings over 30 years of extensive experience in business, including more than two decades in life science start-up financing and company creation. Remiges Ventures operates with a distinctive cross-border strategy, aiming to bridge the entrepreneurial and biotech ecosystems of the United States and Japan, and capitalize on Japan's rich innovation in life sciences. This approach allows them to build new companies based on groundbreaking seed technologies from Japanese researchers while also investing in promising early-stage companies worldwide.

Remiges Ventures boasts a diverse portfolio of companies, reflecting its commitment to advancing medical science. Notable investments include Immunis, which has licensed treatment candidates for Parkinson's disease and announced positive results for sarcopenic seniors; Cyrano Therapeutics, focused on regenerative therapy for smell loss; Glycomine, a provider of replacement therapies for rare genetic diseases; and Kupando, a biopharmaceutical company developing cancer and infectious disease therapies. Other portfolio companies include Viage Therapeutics, Myrodia Therapeutics, Ride Health, KisoJi Biotechnology, IMEL Biotherapeutics, OMEICOS, InFlectis BioScience, Tranquis Therapeutics, and Capacity Bio. The firm's involvement extends to supporting significant research findings, such as those from LUCA Science published in Nature Metabolism, and strategic collaborations like KisoJi Biotechnology's partnership with Cancer Research UK.

The team at Remiges Ventures comprises experienced professionals with deep expertise in the life sciences and investment management. Key members include Managing Partner Taro Inaba, Operating Partner Walter Olesiak, and Partners Takaaki Tobaru and Taka Koda. The team also includes a Director of Finance, additional partners, venture partners, senior associates, investment managers, and advisors. The RDiscovery team further strengthens their scientific capabilities with a Chairman, Chief Medical Officer, scientific advisors, and researchers, ensuring comprehensive support for their portfolio companies from scientific validation to market development.